



OPEN ACCESS

EDITED BY

Alok Raghav,
Gachon University, Republic of Korea

REVIEWED BY

Carol Huang,
University of Calgary, Canada
Aleksandra Jotic,
University of Belgrade, Serbia

*CORRESPONDENCE

Matej Orešič
✉ matej.oresic@utu.fi

RECEIVED 26 April 2023

ACCEPTED 18 August 2023

PUBLISHED 06 September 2023

CITATION

Lamichhane S, Sen P, Dickens AM, Kråkström M, Ilonen J, Lempainen J, Hyöty H, Lahesmaa R, Veijola R, Toppari J, Hyötyläinen T, Knip M and Orešič M (2023) Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children. *Front. Endocrinol.* 14:1211015. doi: 10.3389/fendo.2023.1211015

COPYRIGHT

© 2023 Lamichhane, Sen, Dickens, Kråkström, Ilonen, Lempainen, Hyöty, Lahesmaa, Veijola, Toppari, Hyötyläinen, Knip and Orešič. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children

Santosh Lamichhane¹, Partho Sen¹, Alex M. Dickens^{1,2}, Matilda Kråkström¹, Jorma Ilonen³, Johanna Lempainen^{3,4,5}, Heikki Hyöty^{6,7}, Riitta Lahesmaa^{1,8,9}, Riitta Veijola^{10,11}, Jorma Toppari^{4,12}, Tuulia Hyötyläinen¹³, Mikael Knip^{14,15} and Matej Orešič^{1,16*}

¹Turku Bioscience, University of Turku and Åbo Akademi University, Turku, Finland, ²Department of Chemistry, University of Turku, Turku, Finland, ³Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland, ⁴Department of Pediatrics and Adolescent Medicine, Turku University Hospital, Turku, Finland, ⁵Clinical Microbiology, Turku University Hospital, Turku, Finland, ⁶Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland, ⁷Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland, ⁸InFLAMES Research Flagship Center, University of Turku, Turku, Finland, ⁹Institute of Biomedicine, University of Turku, Turku, Finland, ¹⁰Department of Pediatrics, PEDEGO Research Unit, Medical Research Centre, University of Oulu, Oulu, Finland, ¹¹Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland, ¹²Institute of Biomedicine, Centre for Integrative Physiology and Pharmacology, and Centre for Population Health Research, University of Turku, Turku, Finland, ¹³School of Science and Technology, Örebro University, Örebro, Sweden, ¹⁴Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland, ¹⁵Department of Pediatrics, Tampere University Hospital, Tampere, Finland, ¹⁶School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

Aims/hypothesis: Appearance of multiple islet cell autoantibodies in early life is indicative of future progression to overt type 1 diabetes, however, at varying rates. Here, we aimed to study whether distinct metabolic patterns could be identified in rapid progressors (RP, disease manifestation within 18 months after the initial seroconversion to autoantibody positivity) vs. slow progressors (SP, disease manifestation at 60 months or later from the appearance of the first autoantibody).

Methods: Longitudinal samples were collected from RP (n=25) and SP (n=41) groups at the ages of 3, 6, 12, 18, 24, or ≥ 36 months. We performed a comprehensive metabolomics study, analyzing both polar metabolites and lipids. The sample series included a total of 239 samples for lipidomics and 213 for polar metabolites.

Results: We observed that metabolites mediated by gut microbiome, such as those involved in tryptophan metabolism, were the main discriminators between RP and SP. The study identified specific circulating molecules and pathways, including amino acid (threonine), sugar derivatives (hexose), and quinic acid that may define rapid vs. slow progression to type 1 diabetes. However, the circulating lipidome did not appear to play a major role in differentiating between RP and SP.

Conclusion/interpretation: Our study suggests that a distinct metabolic profile is linked with the type 1 diabetes progression. The identification of specific metabolites and pathways that differentiate RP from SP may have implications for early intervention strategies to delay the development of type 1 diabetes.

KEYWORDS

birth cohort, lipidomics, metabolomics, type 1 diabetes mellitus, gut microbial metabolites

Introduction

Type 1 diabetes is an autoimmune disease that arises due to the destruction of the insulin-producing beta cells in the islets of the pancreas (1). Many exogenous factors have been associated with the development of type 1 diabetes, including viral infections, diet, exposure to toxins and chemicals, and gut microbiota (2–4). The preclinical period of type 1 diabetes is characterized by serum islet autoantibodies. Children who develop multiple (≥ 2) autoantibodies increase the likelihood of clinical type 1 diabetes later in life (5–7), but at varying rate (8). Age at the time of seroconversion and high titers of insulin autoantibodies (IAA) influence the progression rate (9, 10).

Metabolomics studies focusing on a possible link between type 1 diabetes and the circulating metabolome suggest that metabolic dysregulation precedes the clinical presentation of diabetes, prior to an asymptomatic pre-diabetes period (11–13). However, metabolomes of rapid vs. slow progressors to type 1 diabetes following the seroconversion have not yet been investigated. Here we analyzed circulating polar metabolites ('metabolomics') and molecular lipids ('lipidomics') from serum samples obtained from children recruited into the Finnish Type 1 Diabetes Prediction and Prevention study (DIPP), divided into two study groups: children who progressed slowly to overt disease (SP, duration from initial seroconversion to clinical disease ≥ 60 months and children who progressed rapidly (RP) to type 1 diabetes (time from seroconversion to clinical disease ≤ 18 months).

Methods

These methods are adapted versions of descriptions in our related work (14).

Study design and protocol

In this study, the samples were obtained from the Finnish Type 1 Diabetes Prevention and Prediction Study (DIPP) (15), an observational birth cohort study following the participants from the age of 3 months to 15 years of age or to the diagnosis of type 1 diabetes. The DIPP study was initiated in 1994 and is currently

running in three university hospitals in Finland (Oulu, Tampere, and Turku). The participants involved in the current study were chosen from the subset of DIPP children who were born in Turku University Hospital since sequential unfrozen serum samples, collected between 1998 and 2012 and stored at -80°C were available from these participants. The study protocol was approved by the ethics committee of the Hospital District of Southwest Finland. The study was conducted according to the guidelines in the Declaration of Helsinki. All families provided written, informed consent for participation in the study. For each child, longitudinal samples for metabolomics analysis were obtained at the age of 3, 6, 12, 18, 24 or ≥ 36 months (Figure 1).

This study included samples ($n=239$ for lipidomics and $n=213$ for polar metabolites) from 66 children, divided into two groups, being 25 RPs and 41 SPs. Selected characteristics of the participants in this study are listed in Table 1. In this study, non-fasting blood samples were collected, serum was prepared within 3 hours of sample collection and stored at -80°C until analyzed.

HLA genotyping

Screening for HLA-conferred susceptibility to type 1 diabetes was carried out using cord blood samples. The HLA-genotyping was performed with a time-resolved, fluorometry-based assay for four alleles using lanthanide chelate-labelled, sequence-specific oligonucleotide probes detecting DQB1*02, DQB1*03:01, DQB1*03:02, and DQB1*06:02/3 alleles (16). The carriers of DQB1*02/DQB1*03:02 or DQB1*03:02/x genotypes (here $x \neq$ DQB1*03:01, DQB1*06:02, or DQB1*06:03 alleles) were categorized as children with increased HLA susceptibility to type 1 diabetes and accordingly invited to the DIPP follow-up program.

The study participants underwent more extensive HLA genotyping. This genotyping defined all common European HLA-DR-DQ haplotypes at low resolution and at higher resolution haplotypes where this was relevant for the assessment of the risk for type 1 diabetes, e.g. HLA-DR4 subtypes in DR4-DQ8 haplotypes. In a series of 2,991 family trios from the Finnish Pediatric Diabetes Register, the genotype risks were defined and genotypes were combined into six groups from O (strongly protective) to 5 (high risk) which did not overlap for 95% confidence intervals of their OR values for type 1 diabetes (17).




FIGURE 1

An overview of the study design. The study cohort comprised children rapidly progressing to overt type 1 diabetes (RP) and children slowly progressing to clinical disease (SP) during the follow-up until the age of 15 years. For each child, longitudinal serum samples were drawn, corresponding to the age of 3, 6, 12, 18, 24 or ≥ 36 months. Moreover, the age at diagnosis of type 1 diabetes is shown in the participating children.

Detection of islet autoantibodies

The children with HLA-conferred genetic susceptibility were prospectively observed for levels of diabetes-associated autoantibodies [islet cell antibodies (ICA), insulin autoantibodies (IAA), and glutamic acid decarboxylase antibodies (GADA) and insulinoma-like antigen 2 antibodies (IA-2A)]. These autoantibodies were analyzed from serum samples taken at each follow-up visit as previously described (18). ICA levels were determined using an approved, immunofluorescence assay with a detection limit of 2.5 Juvenile Diabetes Foundation Units (JDFU) (19). GADA and IAA levels were quantified using specific radiobinding assays, the threshold of positivity being 5.36 and 3.48 relative units (RU) respectively (20, 21). Similarly, IA-2A levels were measured with a radio-binding assay with a threshold of 0.43 RU (22).

Analysis of molecular lipids

The samples were randomized and extracted using a modified version of the previously-published Folch procedure (23). 10 μ L of serum was mixed with 10 μ L 0.9% NaCl and extracted with 120 μ L of CHCl_3 : MeOH (2:1, v/v) solvent mixture containing internal standard mixture ($c = 2.5 \mu\text{g/ml}$); 1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine [PE(17:0/17:0)], N-heptadecanoyl-D-

erythro-sphingosylphosphorylcholine [SM(d18:1/17:0)], N-heptadecanoyl-D-erythro-sphingosine [Cer(d18:1/17:0)], 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine [PC(17:0/17:0)], 1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(17:0)] and 1-palmitoyl-d31-2-oleoyl-sn-glycero-3-phosphocholine [PC(16:0/d31/18:1)], cholest-5-en-3 β -yl heptadecanoate [CE(17:0)] and, triheptadecanoylglycerol [TG(17:0/17:0/17:0)].

The samples were vortex mixed and incubated on ice for 30 min after which they were centrifuged at $7800 \times g$ for 5 min. Finally, 60 μ L from the lower layer of each sample was collected and mixed with 60 μ L of ice-cold CHCl_3 : MeOH (2:1, v/v) in an LC vial.

The Ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOFMS) analyses were carried out in a similar manner to that described earlier, with some modifications (24, 25). The UHPLC-QTOFMS system was from Agilent Technologies (Santa Clara, CA, USA) combining a 1290 Infinity LC system and 6545 QTOFMS, interfaced with a dual jet stream electrospray (dual ESI) ion source. MassHunter B.06.01 software (Agilent Technologies, Santa Clara, CA, USA) was used for all data acquisition and MZmine 2.53 was used for data processing as described below (26). Identification of lipids was based on in house laboratory LC-MS/MS data on retention time and mass spectra.

Chromatographic separation was performed using an Acquity UPLC BEH C18 column (100 mm $\times$ 2.1 mm i.d., 1.7 μ m particle size) and a C18 precolumn, both from Waters Corporation

TABLE 1 Demographic characteristics of study population.

	RP (n= 25)	SP (n=41)
Gender (girls, boys)	(12, 13)	(19, 22)
Age at time of diagnosis (mean $\pm$ SD)	2.88 $\pm$ 2.34	11.84 $\pm$ 2.80
Age at time of first seroconversion (mean $\pm$ SD)	2.81 $\pm$ 2.28	1.99 $\pm$ 1.19
Interval from seroconversion to type1 diabetes (mean $\pm$ SD)	0.70 $\pm$ 0.37	9.86 $\pm$ 2.53

(Wexford, Ireland). The mobile phases were water (phase A) and acetonitrile:2-propanol (1:1, v/v) (phase B), both containing 1% 1M ammonium acetate and 0.1% (v/v) formic acid ammonium acetate as ionization agents. The LC pump was programmed at a flow rate of 0.4 mL min⁻¹ and the elution gradient was as follows: from min 0–2, the percentage of phase B was modified from 35% to 80%, from min 2–7, the percentage of phase B was modified from 80% to 100% and then, the final percentage was held for 7 min. A post-time of 7 min was used to regain the initial conditions for the next analysis. Thus, the total analysis time per sample was 21 min (including post processing). The settings of the dual ESI ionization source were as follows: capillary voltage 3.6 kV, nozzle voltage 1500 V, N₂ pressure in the nebulizer 21 psi, N₂ flow rate and temperature as sheath gas 11 L min⁻¹ and 379°C, respectively. Accurate mass spectra in the MS scan were acquired in the m/z range 100–1700 in positive ion mode.

The peak area obtained for each lipid was normalized with lipid-class-specific internal standards. A (semi)quantitation was performed using lipid-class-specific calibration curves. Pooled samples were used for quality control, in addition to NIST CR-1950 serum and in-house plasma QC serum. The RSD of the concentrations of the identified lipids in QC samples and pooled extracts was on average 6.3% and 16.2%, respectively.

Analysis of polar metabolites

To a 10 µL aliquot of plasma, 225 µL of ice-cold MeOH (LC-grade, Honeywell) containing the following internal standards (all from Sigma Aldrich): Heptadecanoic acid (5 ppm), DL-valine-d8 (1 ppm), and succinic acid-d4 (1 ppm) was added. The samples were then sonicated in an ice bath for 30 s prior to centrifugation (5500 g, 5 min). 250 µL of the supernatant was transferred to a 2 mL glass auto sampler vial. The pellet was stored at –20°C for protein analysis. The protein content was measured by the Bradford method. The supernatant was dried under a stream of nitrogen at 45°C. Prior to the mass spectrometry measurements, the samples were derivatized using a two-step procedure. Initially the samples were methoximated by incubating the samples with methoxyamine hydrochloride (25 µL, 20mg/mL in pyridine, Sigma Aldrich) at 45°C for 1 h. N-Methyl-N-trimethylsilyltrifluoroacetamide (25 µL, Sigma Aldrich) was then added and the samples were incubated for a further 60 min. A retention index standard containing straight chain, even alkanes (n 10–40, 10 µL, Sigma Aldrich) was added. All this sample prep was performed on a Gerstel robot and timed to the injection into the GC-MS. The derivatized samples were analyzed using gas chromatography (Agilent 7890B) coupled to a time of flight mass spectrometer (Pegasus BT LECO). The metabolites were separated using a 30 m × 0.25 mm (ID) with a film thickness of 0.25 µm HP-5 (Agilent). A guard column (10 m) with an ID of 0.25 mm was used. 1 µL of the sample was injected in split less mode with an inert glass liner (Agilent) held at a temperature of 240°C. The GC was set to constant flow mode (1.2 mL/min) using helium (Aga) as the carrier gas. The GC oven was programmed as follows: 50°C (isothermal for 0.2 min), then 7°C/min until 240°C, then 20°C/min until 300°C (isothermal for 5 min). The transfer line was held at

230°C for the whole run. The ion source was set to electron ionization mode and held at 250°C. The MS was scanning from 50 – 650 Da with an extraction rate of 30 kHz and a scan rate of 16 per second.

Data preprocessing

Lipidomics data processing was performed using open source software MZmine 2.53 (26). The following steps were applied in the processing: 1) Crop filtering with a m/z range of 350 – 1700 m/z and a RT range of 2.0 to 12 min, 2) Mass detection with a noise level of 1200, 3) Chromatogram builder with a minimum time span of 0.08 min, minimum height of 1000 and a m/z tolerance of 0.006 m/z or 10.0 ppm, 4) Chromatogram deconvolution using the local minimum search algorithm with a 70% chromatographic threshold, 0.05 min minimum retention time (RT) range, 5% minimum relative height, 1200 minimum absolute height, a minimum ratio of peak top/edge of 1 and a peak duration range of 0.08 – 5.0, 5) Isotopic peak grouper with a m/z tolerance of 5.0 ppm, RT tolerance of 0.05 min, maximum charge of 2 and with the most intense isotope set as the representative isotope, 6) Join aligner with a m/z tolerance of 0.008 or 10.0 ppm and a weight for of 2, a RT tolerance of 0.1 min and a weight of 1 and with no requirement of charge state or ID and no comparison of isotope pattern, 7) Peak list row filter with a minimum of 12 peaks in a row (= 10% of the samples), 8) Gap filling using the same RT and m/z range gap filler algorithm with an m/z tolerance of 0.006 m/z or 10.0 ppm, 9) Identification of lipids using a custom database search with an m/z tolerance of 0.006 m/z or 10.0 ppm and a RT tolerance of 0.1 min, 10) Normalization using lipid-class-specific internal standards and (semi) quantitation with lipid-class-specific calibration curves, 11) Normalization with total protein amount 12) Data imputation of missing values were done with half of the row's minimum.

The GC-QMS data was processed in ChromaTOF (v5.51, LECO) using the peak find algorithm. The peak intensities were normalized to heptadecanoic acid. The peaks were manually checked and corrected if needed for correct integration. Metabolites which had a coefficient of variation greater than 30% in the pooled quality control sample or fell below the limit of quantification were excluded from subsequent analysis.

Statistical methods

The metabolites and lipids data values were log transformed prior to analysis. The difference in the lipidome and metabolome between the studies groups were compared using a multivariate linear model. For longitudinal samples, linear mixed effects model were regressed with fixed effect (~ sex + case + age) and random effect ~ (1 | Subject). For age wise comparisons the lipids/ metabolites were regressed with various factors such as sex, and disease conditions (e.g. RP vs. SP) using MaAsLin2 package in R (lipids ~ sex + case). To subsequently visualize metabolite level, violin plots from the ggplot2 R package were used.

Pathway analysis of the significant metabolites (p -value < 0.05) was performed in MetaboAnalyst 5.0 (27). The compounds unmatched during compound name matching were excluded from the subsequent pathway analysis. We implemented global test hypergeometric testing for the functional enrichment analysis. The pathway topological analysis was based on the relative betweenness measures of a metabolite in a given metabolic network and for calculating the pathway impact score. Based on the impact values from the pathway topology analysis, the impact value threshold was set to > 0.10 .

Results

Global metabolome and lipidome in rapid vs. slow progressors to type 1 diabetes


We performed untargeted metabolomics and lipidomics analysis in a longitudinal setting among two study groups: 25 rapid progressors who progressed to type 1 diabetes within 18 months after the appearance of the first autoantibody (RP) and 41 slow progressors, who presented with clinical disease after a period of at least 60 months from the initial seroconversion to clinical disease (SP). For each child, samples were analyzed from up to six time points, corresponding to the ages of 3, 6, 12, 18, 24, or ≥ 36 months (Figure 1). The lipidomics dataset ($n = 239$) included the identified lipids from the following lipid classes: cholesterol esters (CE), ceramides (Cer), diacylglycerols (DG), lysophosphatidylcholines (LPC), phosphatidylcholines (PC), phosphatidylethanolamines (PE), sphingomyelins (SM), and triacylglycerols (TG). Metabolomic dataset ($n = 213$) included the

metabolites from chemical classes, including amino acids, carboxylic acids, phenolic compounds, sugars, and sugar derivatives.

To identify the sources of variation in the lipidomics and metabolomics datasets, multivariable linear model was performed. The concentrations of lipids/metabolites were regressed on factors including age, sex, and case-related phenotypes (e.g., SP vs. RP). Among these factors, age showed the strongest effect on the circulating lipidomics and metabolomics profiles. A total of 44 polar metabolites and 106 lipids were related to age (p -value < 0.05 , Supplementary Material SM Tables 1, 2). A total of 35 out of 175 lipids differed between male and female in the longitudinal setting (p -value < 0.05 , SM Table 3). However, no sex differences were observed in the metabolomics dataset.

A total of 21 polar metabolites differed between the study groups (SP vs. RP; p -value < 0.05 , Figure 2, SM Table 4). The tryptophan-derived microbial catabolite 3-indole acetic acid was downregulated in the SP group (Figures 2A, B, p -value < 0.05). While most of the sugar derivatives were upregulated in the RP compared to the SP group, quinic acid remained upregulated in the SP group (Figure 2C). Figures 2A–C shows the local polynomial regression fitting (LOESS) plot of selected metabolite class with time for the case-related phenotypes.

Considering that age is a confounding factor in the metabolomics analysis, we also performed age-matched comparisons between SP and RP (Figure 2D). We found that the main metabolic differences between these two groups were after the median age of seroconversion (i.e., around 24–36 months of age). The result showed that at the age of 3, 6, 12, 18, 24 and ≥ 36 months, a total of 12, 3, 2, 14, 17 and 23, metabolic features were altered, respectively, between the study groups (Figure 2D).



Next, the changes in plasma lipid concentration between the study groups in the longitudinal series sample collection were examined. We found that lipid-related differences were less pronounced as compared to polar metabolites. Levels of two lipids, PE (34:0) and TG (18:2/18:1/18:1), were different between SP and RP (p-value < 0.05). With the exception of lipid PE (34:0), there was no consistent lipid related trend between the study groups. The age-wise comparison showed that at the age of 3, 6, 12, 18, 24 or ≥ 36 months, a total of 1, 1, 1, 13, 3 and 10 lipids were different between the SP and RP groups, respectively (ESM Figure S1).

As progression of type 1 diabetes is associated with distinct islet autoantibody trajectories, we compared differences in metabolite changes in relation to the development of specific islet autoantibodies (IAA vs. others). With the exceptions of a carboxylic acid derivative, no other differences (p-value < 0.05) between the IAA vs. other autoantibodies were observed, which may be due to the small sample size per autoantibody grouping.

Metabolic pathways discriminating fast vs. slow progressors to type 1 diabetes

We then examined the differences between the SP and RP groups at the metabolic pathway level. The selected metabolites/lipids that differed between the case-related phenotypes (SP vs. RP) were subjected to metabolic pathway analysis in MetaboAnalyst 5, integrating enrichment-based analysis and pathway topology analysis. Using pathway impact estimates, we found that mainly amino acid-related metabolic processes including phenylalanine, tyrosine and tryptophan biosynthesis, ascorbate and aldarate

metabolism, and tyrosine metabolism, pentose and glucuronate interconversions were different between SP and RP (SM Figure S2, impact value threshold was set to >0.10).

Metabolic alterations before and after the first appearance of islet autoantibodies in rapid and slow progressors to type 1 diabetes

We also studied the metabolic changes between the SP and RP groups (1) prior to the appearance of islet autoantibodies and (2) after the first appearance of islet autoantibodies. We identified differences in polar metabolite profiles after the appearance of the first islet autoantibody when comparing rapid and slow progressors to type 1 diabetes. Altogether, 13 metabolites remained upregulated in rapid progressors as compared to slow progressors (p-value < 0.05, SM Figure S3). These metabolites can be divided into major chemical classes including sugars, amino acids, and a microbiota-derived metabolite indole-3-acetic acid (*i.e.*, tryptophan catabolite). Among these 13 metabolites, comparative profiles of indole-3-acetic, threonine, beta-tocopherol and hexose are shown in Figure 3 (p-value < 0.05, ESM Table 5). We also analyzed metabolite concentration differences between rapid progressors and slow progressors prior to the appearance of islet autoantibodies. Quinic acid and an unknown metabolite were downregulated in rapid progressors when compared to slow progressors before seroconversion (p-value < 0.05).

Next, we studied whether lipidomic patterns were related to the development of islet autoantibodies. For that, we analyzed the lipid concentration differences between rapid and slow progressors




FIGURE 3

Polar metabolite profiles in serum before and after the first appearance of islet autoantibodies comparing rapid (RP) and slow progressors (SP) to type 1 diabetes. (A–D) Violin plot showing the selected discriminating metabolites between the SP and RP. Here, RP and SP is analyzed after the appearance of the first islet autoantibody.

before and after the emergence of the first islet autoantibody. The results revealed weak differences in lipid levels between the slow and rapid progressors, after or before seroconversion to islet autoantibody positivity. We found two lipid species [PE (O-16:0/22:6) and Cer (d18:1/24:0)] downregulated in slow progressors after the appearance of first islet autoantibodies, when compared to rapid progressors (p-value <0.05). Likewise, there were two lipids [PC (O-38:6) and PE (34:0)] that differed between rapid and slow progressors before the appearance of the first islet autoantibodies (p-value <0.05).

Discussion

Our study identified specific associations between the metabolic profiles and rate of progression to type 1 diabetes. We observed that specific sugar derivatives and microbial metabolites differed between rapid and slow progressors. While our findings are in line with previous studies showing that metabolic dysregulation precedes islet autoimmunity and type 1 diabetes (11–14), here we showed that after seroconversion to islet autoantibody positivity, slow and rapid progression to clinical diabetes are metabolically different. In agreement with earlier findings (13, 28), we also observed that age was the major confounder in the metabolomics/lipidomics studies.

Recent literature suggests that the gut microbiota is associated with the pathogenesis of type 1 diabetes, however, mechanisms by which gut microbes contribute to the initiation and progression of this disease remain to be identified (29–32). We found that the microbiota-derived metabolite 3-indole-acetic acid was upregulated in children who rapidly progressed to type 1 diabetes following the seroconversion to autoantibody positivity. Previous studies have shown that dysregulated microbial metabolites were associated with the manifestation of type 1 diabetes (33, 34). The microbiota-derived indole metabolites promote intestinal homeostasis and are known for their immunomodulatory signaling activity (34–36). 3-indole-acetic acid is a tryptophan-derived metabolite known to be produced by multiple gut bacterial species, including *Bacteroides*, *Bifidobacterium*, *Clostridium* and *Eubacterium* (37). Tryptophan, an essential amino acid, is obtained from dietary protein sources. Increase in tryptophan catabolites (*i.e.*, 3-indole-acetic acid) in circulation suggests a shift from saccharolytic to proteolytic fermentation in the gut among the rapid progressors (38). In line with this, Vatanen et al. showed that microbiota of children who progressed to type 1 diabetes contained less genes that were related to saccharolytic fermentation (29). Thus, the most plausible explanation for the observed elevated 3-indole-acetic acid in the rapid progressors is that the shift in microbial fermentative energy sources dysregulates microbial tryptophan catabolism, which, in turn, exacerbated the pathogenic processes contributing to type 1 diabetes.

Our findings suggest that increasing levels of sugar derivatives in the peripheral circulation (*e.g.*, hexose) contribute to the accelerated progression to type 1 diabetes. The levels of these

metabolites were increased in rapid progressors (*vs.* slow) only after the initial appearance of islet autoantibodies. An increased level of sugars in circulation demands higher insulin secretion, leading to beta-cell stress that could contribute to rapid progression to symptomatic type 1 diabetes (39). Recently, in the TRIGR study, Ludvigsson et al. showed that the first appearance of islet cell autoantibody may be related to the increased glucose concentration in blood, corroborating the beta-cell stress hypothesis (40). Intriguingly, Helminen et al. also showed that random plasma glucose predicted the progression to clinical type 1 diabetes in high-risk children (41). We hypothesize that increased insulin demand due to upregulated sugar molecules in the circulation is one of the non-exclusive triggers contributing to the rapid manifestation of type 1 diabetes. Additionally, differences in autoantibody and HLA profiles between RP and SP could affect the individual's metabolic profile (42). However, we observed minor metabolic dissimilarities linked to the autoantibody profile, particularly between those with IAA presence and those with other autoantibodies. These variances might be due to the small sample size within each autoantibody subgroup.

Growing evidence suggests abnormal lipid metabolism preceding seroconversion to autoantibody positivity and clinical type 1 diabetes (43–46). We also observed changes, albeit subtle, in the levels of phospholipid species in the group of rapid progressors as compared to slow progressors, particularly before seroconversion. However, the earlier studies compared healthy individuals with children *en route* to overt type 1 diabetes, not the rate of progression among the latter subjects.

We acknowledge limitations of this study, one of them being the relatively small sample size in our longitudinal setting. However, to the best of our knowledge, this study presents a novel association of microbiota-derived metabolites, which served as the main discriminators between RP and SP. Next, data on the intestinal microbiome and diet are not available from the study participants. Since microbiota-derived metabolites are crucial in mediating health impacts of the intestinal microbiome, future work could assess the impact of diet–microbe interactions in the progression of type 1 diabetes. Notwithstanding this, our study generates novel hypotheses; however, the causal relationship still remains unknown. With further validation, these findings could advance future research on the disease process leading to clinical type 1 diabetes.

Taken together, our study suggests that a distinct metabolic profile is associated with the rate of progression to type 1 diabetes. The identification of specific metabolites and pathways that differentiate RP from SP may have implications for early intervention strategies to delay or prevent the development of type 1 diabetes.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The study protocol was approved by the ethics committee of the Hospital District of Southwest Finland. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin.

Author contributions

Conceptualization: MO, RL, and MKn. Data curation: MKr, PS, and AD. Formal analysis: SL and PS. Funding acquisition: MO, MKn, TH, JT, and RL. Investigation: SL, MO, TH, JT, and MK. Methodology: TH, MKr, and AD. Resources: RV, RL, JT, JI, HH, JL, and MKn. Supervision: TH, MKn, and MO. Writing – first draft: SL. Writing – critical review & editing: all authors. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Novo Nordisk Foundation (NNF18OC0034506, to MO), Juvenile Diabetes Research Foundation (2-SRA-2014-159-Q-R, to MO, TH, RL, and MKn), Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research – SyMMyS, Decision No. 250114, to RL, JT, MO, RL, and MKn; and Personalised Health 2014 programme project, Decision No. 292568, to RL, JT, MO, RL, and MKn). Further support was received by the Academy of Finland postdoctoral grant (No. 323171 to SL) and (grant no. 333981 to MO), “Inflammation in human early life: targeting impacts on life-course health” (INITIALISE) consortium funded by the Horizon Europe Program of the European Union under Grant Agreement 101094099 (to MO), the Medical Research Funds, Tampere and

Helsinki University Hospitals (to MKn), InFLAMES Flagship Programme of the Academy of Finland (decision number: 337530) and Turku University Hospital (to MO, RL, and JT).

Acknowledgments

We thank the families participating in the DIPP study for making this study possible. We also thank the expert staff of the DIPP study for their excellent work with the participating research families and sample collection. We thank Professor Olli Simell for his important scientific contribution to the DIPP study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fendo.2023.1211015/full#supplementary-material>

References

- Katsarou A, Gudbjörnsdóttir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. *Nat Rev Dis Primers* (2017) 3:17016. doi: 10.1038/nrdp.2017.16
- Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. *Diabetes* (2005) 54 Suppl 2:S125–36. doi: 10.2337/diabetes.54.suppl_2.S125
- Rewers M, Hyöty H, Lernmark Å, Hagopian W, She JX, Schatz D, et al. The environmental determinants of diabetes in the young (TEDDY) study: 2018 update. *Curr Diabetes Rep* (2018) 18:136. doi: 10.1007/s11892-018-1113-2
- Predieri B, Bruzzi P, Bigi E, Ciancia S, Madeo SF, Lucaccioni L, et al. Endocrine disrupting chemicals and type 1 diabetes. *Int J Mol Sci* 21 (2020) 21(8):293. doi: 10.3390/ijms21082937
- Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA* (2013) 309:2473–9. doi: 10.1001/jama.2013.6285
- Jia X, Gu Y, High H, Yu L. Islet autoantibodies in disease prediction and pathogenesis. *Diabetol Int* (2020) 11:6–10. doi: 10.1007/s13340-019-00414-9
- Anand V, Li Y, Liu B, Ghalwash M, Koski E, Ng K, et al. Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: joint analyses of prospective cohort studies in Finland, Germany, Sweden, and the U.S. *Diabetes Care* (2021) 44:2269–76. doi: 10.2337/dc20-1836
- Achenbach P, Hummel M, Thümer L, Boerschmann H, Höfelmann D, Ziegler AG. Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. *Diabetologia* (2013) 56:1615–22. doi: 10.1007/s00125-013-2896-y
- Steck AK, Johnson K, Barriga KJ, Miao D, Yu L, Hutton JC, et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. *Diabetes Care* (2011) 34:1397–9. doi: 10.2337/dc10-2088
- Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler AG, Hagopian WA, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The environmental determinants of diabetes in the young (TEDDY). *Diabetes Care* (2015) 38:808–13. doi: 10.2337/dc14-2426
- Lamichhane S, Kempainen E, Tröst K, Siljander H, Hyöty H, Ilonen J, et al. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes. *Diabetologia* (2019) 62:2287–97. doi: 10.1007/s00125-019-04980-0
- Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, Parikka V, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. *J Exp Med* (2008) 205:2975–84. doi: 10.1084/jem.20081800
- Lamichhane S, Ahonen L, Dyrland TS, Kempainen E, Siljander H, Hyöty H, et al. Dynamics of plasma lipidome in progression to islet autoimmunity and type 1

- diabetes - type 1 diabetes prediction and prevention Study (DIPP). *Sci Rep* (2018) 8:10635. doi: 10.1038/s41598-018-28907-8
14. Sen P, Dickens AM, López-Bascón MA, Lindeman T, Kemppainen E, Lamichhane S, et al. Metabolic alterations in immune cells associate with progression to type 1 diabetes. *Diabetologia* (2020) 63:1017–31. doi: 10.1007/s00125-020-05107-6
 15. Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Hamalainen AM, et al. Juvenile Diabetes Research Foundation Centre for the Prevention of Type, Feasibility of genetic and immunological prediction of type 1 diabetes in a population-based birth cohort. *Diabetologia* (2001) 44:290–7. doi: 10.1007/s001250051616
 16. Ilonen J, Reijonen H, Herva E, Sjöroos M, Iitua A, Lovgren T, et al. Rapid HLA-DQB1 genotyping for four alleles in the assessment of risk for IDDM in the Finnish population. The Childhood Diabetes in Finland (DiMe) Study Group. *Diabetes Care* (1996) 19:795–800. doi: 10.2337/diacare.19.8.795
 17. Ilonen J, Kiviniemi M, Lempainen J, Simell O, Toppari J, Veijola R, et al. Genetic susceptibility to type 1 diabetes in childhood - estimation of HLA class II associated disease risk and class II effect in various phases of islet autoimmunity. *Pediatr Diabetes* (2016) 17 Suppl 22:8–16. doi: 10.1111/pedi.12327
 18. Siljander HT, Simell S, Hekkala A, Lähde J, Simell T, Vähäsalo P, et al. Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. *Diabetes* (2009) 58:2835–42. doi: 10.2337/db08-1305
 19. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. *Lancet* (1974) 2:1279–83. doi: 10.1016/S0140-6736(74)90140-8
 20. Savola K, Sabbah E, Kulmala P, Vahasalo P, Ilonen J, Knip M. Autoantibodies associated with Type 1 diabetes mellitus persist after diagnosis in children. *Diabetologia* (1998) 41:1293–7. doi: 10.1007/s001250051067
 21. Ronkainen MS, Hamalainen AM, Koskela P, Akerblom HK, Knip M. Pregnancy induces nonimmunoglobulin insulin-binding activity in both maternal and cord blood serum. *Clin Exp Immunol* (2001) 124:190–6. doi: 10.1046/j.1365-2249.2001.01506.x
 22. Savola K, Bonifacio E, Sabbah E, Kulmala P, Vahasalo P, Karjalainen J, et al. IA-2 antibodies—a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group. *Diabetologia* (1998) 41:424–9. doi: 10.1007/s001250050925
 23. Folch J, Lees M, Sloane Stanley G. A simple method for the isolation and purification of total lipids from animal tissues. *J Biol Chem* (1957) 226:497–509. doi: 10.1016/S0021-9258(18)64849-5
 24. Nygren H, Seppanen-Laakso T, Castillo S, Hyötyläinen T, Oresic M. Liquid chromatography-mass spectrometry (LC-MS)-based lipidomics for studies of body fluids and tissues. *Methods Mol Biol* (2011) 708:247–57. doi: 10.1007/978-1-61737-985-7_15
 25. Pedersen HK, Forslund SK, Gudmundsdottir V, Petersen AO, Hildebrand F, Hyötyläinen T, et al. A computational framework to integrate high-throughput 'omics' datasets for the identification of potential mechanistic links. *Nat Protoc* (2018) 13:2781–800. doi: 10.1038/s41596-018-0064-z
 26. Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. *BMC Bioinform* (2010) 11:395. doi: 10.1186/1471-2105-11-395
 27. Pang Z, Chong J, Zhou G, de Lima Moraes DA, Chang L, Barrette M, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. *Nucleic Acids Res* (2021) 49:W388–w396. doi: 10.1093/nar/gkab382
 28. Rist MJ, Roth A, Frommherz L, Weinert CH, Krüger R, Merz B, et al. Metabolite patterns predicting sex and age in participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study. *PloS One* (2017) 12:e0183228. doi: 10.1371/journal.pone.0183228
 29. Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature* (2018) 562:589–94. doi: 10.1038/s41586-018-0620-2
 30. Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. *Cell* (2016) 165:842–53. doi: 10.1016/j.cell.2016.04.007
 31. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. *Nat Rev Endocrinol* (2016) 12:154–67. doi: 10.1038/nrendo.2015.218
 32. Zheng P, Li Z, Zhou Z. Gut microbiome in type 1 diabetes: A comprehensive review. *Diabetes Metab Res Rev* (2018) 34:e3043. doi: 10.1002/dmrr.3043
 33. Galderisi A, Pirillo P, Moret V, Stocchero M, Gucciardi A, Perilongo G, et al. Metabolomics reveals new metabolic perturbations in children with type 1 diabetes. *Pediatr Diabetes* (2018) 19:59–67. doi: 10.1111/pedi.12524
 34. Balderas C, Rupérez FJ, Ibañez E, Señorans J, Guerrero-Fernández J, Casado IG, et al. Plasma and urine metabolic fingerprinting of type 1 diabetic children. *Electrophoresis* (2013) 34:2882–90. doi: 10.1002/elps.201300062
 35. Hubbard TD, Murray IA, Bisson WH, Lahoti TS, Gowda K, Amin SG, et al. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. *Sci Rep* (2015) 5:12689. doi: 10.1038/srep12689
 36. Alexeev EE, Lanis JM, Kao DJ, Campbell EL, Kelly CJ, Battista KD, et al. Microbiota-derived indole metabolites promote human and murine intestinal homeostasis through regulation of interleukin-10 receptor. *Am J Pathol* (2018) 188:1183–94. doi: 10.1016/j.ajpath.2018.01.011
 37. Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. *Nat Commun* (2018) 9:3294. doi: 10.1038/s41467-018-05470-4
 38. Windey K, De Preter V, Verbeke K. Relevance of protein fermentation to gut health. *Mol Nutr Food Res* (2012) 56:184–96. doi: 10.1002/mnfr.201100542
 39. Ludvigsson J. Why diabetes incidence increases—a unifying theory. *Ann N Y Acad Sci* (2006) 1079:374–82. doi: 10.1196/annals.1375.058
 40. Ludvigsson J, Cuthbertson D, Becker DJ, Kordonouri O, Aschmeier B, Pacaud D, et al. Increasing plasma glucose before the development of type 1 diabetes—the TRIGR study. *Pediatr Diabetes* (2021) 22:974–81. doi: 10.1111/pedi.13251
 41. Helminen O, Aspholm S, Pokka T, Ilonen J, Simell O, Veijola R, et al. OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis. *Diabetologia* (2015) 58:1787–96. doi: 10.1007/s00125-015-3621-9
 42. Pöllänen PM, Lempainen J, Laine AP, Toppari J, Veijola R, Vähäsalo P, et al. Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility. *Diabetologia* (2017) 60:1284–93. doi: 10.1007/s00125-017-4258-7
 43. Balzano-Nogueira L, Ramirez R, Zamkovaya T, Dailey J, Ardisson AN, Chamala S, et al. Integrative analyses of TEDDY omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes. *Genome Biol* (2021) 22:39. doi: 10.1186/s13059-021-02262-w
 44. Afshinnia F, Rajendran TM, He C, Byun J, Montemayor D, Darshi M, et al. Circulating free fatty acid and phospholipid signature predicts early rapid kidney function decline in patients with type 1 diabetes. *Diabetes Care* (2021) 44:2098–106. doi: 10.2337/dc21-0737
 45. Holm LJ, Krogvold L, Hasselby JP, Kaur S, Claessens LA, Russell MA, et al. Abnormal islet sphingolipid metabolism in type 1 diabetes. *Diabetologia* (2018) 61:1650–61. doi: 10.1007/s00125-018-4614-2
 46. Oresic M. Metabolomics in the studies of islet autoimmunity and type 1 diabetes. *Rev Diabetes Stud* (2012) 9:236–47. doi: 10.1900/RDS.2012.9.236